AOD-9604 half-life: why a human 30-minute value is unestablished, what pig IV data show, and why clearance claims cannot determine injection frequency.
A human subcutaneous AOD-9604 half-life of about 30 minutes is not established by the evidence in FDA's 2024 evaluation. That review identified no human pharmacokinetic studies for any route. A repeated online half-life cannot justify daily, split, fasted, or pre-workout injections.
The useful distinction is between a measured value in a particular species and route and an assumed human value. This page explains what the reviewed pharmacokinetic evidence can and cannot tell us.
What Is AOD 9604?
AOD-9604 contains hGH residues 177-191 with an additional N-terminal tyrosine, making a modified 16-amino-acid peptide. The common name HGH fragment 176-191 should not be read as an unchanged native sequence.
Unlike full HGH, AOD 9604 does not appear to stimulate IGF-1 production or cause acromegaly-like effects in animal studies. However, human data remain limited, and the peptide is not approved by the FDA for weight loss or any other medical use.
AOD 9604 Half-Life: The Basics
Half-life describes the decline in a measured concentration during a specified phase and study context. FDA's 2024 AOD-9604 evaluation summarizes an approximately three-minute half-life after intravenous administration in pigs; that is not a human or subcutaneous half-life.
An animal intravenous value cannot establish how quickly a human subcutaneous product is absorbed or cleared, how long any effect lasts, or how often it should be administered.
How Half-Life Affects Dosing Frequency
For aod 9604 dosage protocol claims, an assumed 30-minute half-life does not establish a need for frequent administration. Even a valid half-life alone would not determine an effective or safe regimen.
The larger oral obesity trial summarized in FDA's 2024 AOD-9604 evaluation enrolled 536 people and randomized 502 to placebo or 0.25, 0.5, or 1 mg daily for 24 weeks. It did not show a significant advantage on the primary weight-loss endpoint at 12 weeks. Oral trial arms are not human injection recommendations.
Factors That Influence AOD 9604 Clearance
Absorption and clearance can depend on formulation, route, and physiology, but the size of these effects for human AOD-9604 has not been established by the reviewed data.
- Injection site or body composition cannot be assigned a quantified effect without human data.
- Kidney-function effects on human AOD-9604 clearance need direct evidence.
- Concomitant medicines do not supply a known interaction or half-life correction.
- Formulation and route must match the study from which a value is taken.
Aod 9604 with tirzepatide does not have a validated pharmacokinetic or clinical combination profile in the reviewed evidence. A combination's unknowns should not be presented as a measured half-life effect.
How AOD 9604 Compares to Other Peptides
Half-life comparisons are meaningful only when species, route, formulation, measurement, and source are specified. Avoid assigning unsupported human values to different research peptides.
| Compound | How to interpret half-life information |
|---|---|
| AOD-9604 | No human PK studies identified in the 2024 evaluation; pig IV data are not a human SC value |
| MOTS-c | Requires its own species- and route-specific source |
| Retatrutide | Investigational clinical data must be identified by study and formulation |
| Tirzepatide | Use the specific approved product's pharmacokinetic labeling |
| BPC-157 | Do not relabel animal observations as human injection kinetics |
Neither aod 9604 vs mots-c nor aod 9604 vs retatrutide supports a numerical human half-life comparison without suitable sources. It is incorrect to conclude that human AOD-9604 clears within minutes from an animal intravenous result.
Practical Considerations for Handling AOD 9604
Aod-9604 gelling up and other preparation concerns need formulation-specific investigation. Bacteriostatic water is not automatically a compatible solvent for every product.
The 2024 evaluation explains that formulation, pH, concentration, temperature, impurities, and excipients can affect aggregation and degradation. It does not validate one diluent, acid recipe, or shelf life for every AOD-9604 product. Use validated preparation and storage conditions rather than a universal swirl-and-refrigerate rule.
AOD-9604 did undergo human clinical development, including the larger oral trial. It is not FDA-approved, but it is inaccurate to summarize the record as only small injection trials.
Safety and Legal Status
AOD-9604 has no FDA-approved human drug product. A research-use listing does not establish lawful human treatment; legal requirements for a product or practice should not be reduced to blanket purchasing or possession claims.
Potential side effects of AOD 9604 are not well characterized in humans. Some users report injection site reactions, headaches, or fatigue. Because it is a growth hormone fragment, there is a theoretical risk of immune reactions or unexpected hormonal effects. Anyone with a medical condition or taking prescription medications should consult a doctor before considering any peptide.
Key Takeaways on AOD 9604 Half-Life
- No human AOD-9604 half-life was established by the 2024 FDA evaluation.
- The approximately three-minute pig IV value is species- and route-specific.
- A half-life alone does not establish injection frequency, fasting rules, or clinical benefit.
- Comparisons require matched, sourced pharmacokinetic evidence.
- AOD-9604 has no FDA-approved human drug product.
The practical answer is uncertainty about human pharmacokinetics, rather than a 30-minute dosing rule. Safety, exposure, and clinical effectiveness are separate questions and cannot be settled by an assumed clearance time.
Frequently Asked Questions
What is the half-life of AOD 9604?
A human half-life is not established by the 2024 FDA evaluation, which identified no human pharmacokinetic studies for any route. The review describes an approximately three-minute half-life after intravenous administration in pigs; that is not a human subcutaneous value.
How often should AOD 9604 be injected given its half-life?
No injection frequency follows from an assumed 30-minute half-life. Human subcutaneous exposure and kinetics were not established in the review, and even a measured half-life alone would not establish an effective or safe regimen.
Is AOD 9604 FDA-approved?
No FDA-approved AOD-9604 human drug product exists. Historical oral and intravenous development does not validate a human subcutaneous dose, half-life, or schedule.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.